Evaluation of Gynecological and Sexual Sequelae in Patients Treated for Rectal Cancer

What this Trial Is About

Rectal cancer represents about 40% of colorectal cancers, with around 15,000 new cases annually in France and a 5-year survival rate of 55% across all stages. Treatment usually involves surgical removal of the rectum, often combined with preoperative chemoradiotherapy and sometimes immunotherapy based on tumor characteristics. While these treatments improve recurrence-free survival, they can cause long-term complications affecting the digestive, urinary, gynecological, and sexual systems due to anatomical changes and nerve damage. This observational study focuses on women treated for rectal cancer, specifically evaluating the prevalence and features of gynecological and sexual side effects after their treatment. Data are collected through questionnaires including FSFI, QLQ-CR29, QLQ-C30, and the GynéRect questionnaire during a single follow-up visit. The study aims to better understand these side effects to improve prevention, assessment, and management, ultimately optimizing patients' quality of life. Participants will complete questionnaires assessing sexual dysfunction and gynecological sequelae during one follow-up visit. Researchers will analyze these responses to determine the prevalence and characteristics of these issues, identify risk factors, and evaluate the usefulness of the GynéRect questionnaire. The study measures the impact of these sequelae on overall quality of life, with involvement lasting a single day for data collection and evaluation.

Evaluation of Gynecological and Sexual Sequelae